open access

Vol 14, No 2 (2017)
Review paper
Get Citation

The unique effects of aripiprazole on cognitive functions: a place in the treatment of adolescents and elderly patients

Paweł Mierzejewski
Psychiatria 2017;14(2):78-84.

open access

Vol 14, No 2 (2017)
Prace poglądowe - nadesłane

Abstract

Aripiprazole is an antipsychotic drug with unique pharmacological properties, being an ago-antagonist of D2 receptor, classified as a 3rd generation antipsychotic. Clinical and pre-clinical studies indicate significant clinical efficacy and safety of aripiprazole in the treatment of either patients under the age of 18 or in elderly patients. This is due both to its high safety profile and the lack of negative influence on cognitive functions. These features distinguish aripiprazole from other antipsychotics. The aim of the present article is to show the unique properties of aripiprazole, review the clinical trials and discuss of the use of aripiprazole in the treatment of the above-mentioned age groups of patients. Despite its beneficial effect on cognitive function, it should be underlined its positive effect on prolactin level and its use in patients with drug induced hyperprolactinemia.

Abstract

Aripiprazole is an antipsychotic drug with unique pharmacological properties, being an ago-antagonist of D2 receptor, classified as a 3rd generation antipsychotic. Clinical and pre-clinical studies indicate significant clinical efficacy and safety of aripiprazole in the treatment of either patients under the age of 18 or in elderly patients. This is due both to its high safety profile and the lack of negative influence on cognitive functions. These features distinguish aripiprazole from other antipsychotics. The aim of the present article is to show the unique properties of aripiprazole, review the clinical trials and discuss of the use of aripiprazole in the treatment of the above-mentioned age groups of patients. Despite its beneficial effect on cognitive function, it should be underlined its positive effect on prolactin level and its use in patients with drug induced hyperprolactinemia.

Get Citation

Keywords

aripiprazole, cognitive functions, patients under the age of 18, elderly patients

About this article
Title

The unique effects of aripiprazole on cognitive functions: a place in the treatment of adolescents and elderly patients

Journal

Psychiatria (Psychiatry)

Issue

Vol 14, No 2 (2017)

Article type

Review paper

Pages

78-84

Bibliographic record

Psychiatria 2017;14(2):78-84.

Keywords

aripiprazole
cognitive functions
patients under the age of 18
elderly patients

Authors

Paweł Mierzejewski

References (38)
  1. Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010; 16(5): 488–501.
  2. Kirino E. Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents. Adolesc Health Med Ther. 2014; 5: 211–221.
  3. Nagai T, Murai R, Matsui K, et al. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl). 2009; 202(1-3): 315–328.
  4. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004; 18(4): 251–267.
  5. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003; 28(8): 1400–1411.
  6. Urban JD, Vargas GA, von Zastrow M, et al. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology. 2007; 32(1): 67–77.
  7. Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther. 1995; 274(1): 329–336.
  8. Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006; 21(12): 2078–2081.
  9. Schreiber R, Newman-Tancredi A. Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation. Neurobiol Learn Mem. 2014; 110: 72–80.
  10. Bervoets C, Morrens M, Vansteelandt K, et al. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study. CNS Drugs. 2012; 26(11): 975–982.
  11. Matsuda Y, Sato S, Iwata K, et al. Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia. Psychiatry Clin Neurosci. 2014; 68(6): 425–431.
  12. Maat A, Cahn W, Gijsman HJ, et al. Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia. Eur Neuropsychopharmacol. 2014; 24(4): 575–584.
  13. Sakurai H, Bies RR, Stroup ST, et al. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull. 2013; 39(3): 564–574.
  14. Uchida H, Rajji TK, Mulsant BH, et al. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J Clin Psychopharmacol. 2009; 29(6): 571–575.
  15. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry. 2004; 55(10): 1013–1022.
  16. Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res. 2007; 89(1-3): 211–224.
  17. Kołaczkowski M, Mierzejewski P, Bienkowski P, et al. Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia. Naunyn Schmiedebergs Arch Pharmacol. 2014; 387(6): 545–557.
  18. Lewinsohn PM, Hops H, Roberts RE, et al. Adolescent psychopathology: I. Prevalence and incidence of depression and other DSM-III-R disorders in high school students. J Abnorm Psychol. 1993; 102(1): 133–144.
  19. Van Meter AR, Moreira AL, Youngstrom EA. Meta-analysis of epidemiologic studies of pediatric bipolar disorder. J Clin Psychiatry. 2011; 72(9): 1250–1256.
  20. Rasimas JJ, Liebelt EL. Adverse Effects and Toxicity of the Atypical Antipsychotics: What is Important for the Pediatric Emergency Medicine Practitioner. Clin Pediatr Emerg Med. 2012; 13(4): 300–310.
  21. Doey T. Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review. J Affect Disord. 2012; 138 Suppl: S15–S21.
  22. Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008; 165(11): 1432–1441.
  23. Findling RL, Correll CU, Nyilas M, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009; 70(10): 1441–1451.
  24. Findling RL, Correll CU, Nyilas M, et al. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disord. 2013; 15(2): 138–149.
  25. Fraguas D, Correll CU, Merchán-Naranjo J, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol. 2011; 21(8): 621–645.
  26. McKeage K. Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder. CNS Drugs. 2014; 28(2): 171–183.
  27. Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol. 2011; 21(8): 600–620.
  28. Ghanizadeh A. Systematic review of clinical trials of aripiprazole for treating attention deficit hyperactivity disorder. Neurosciences (Riyadh). 2013; 18(4): 323–329.
  29. Lamberti M, Siracusano R, Italiano D, et al. Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study. Paediatr Drugs. 2016; 18(4): 319–329.
  30. Filipska K, Pietrzykowski Ł, Ciesielska N, et al. Zaburzenia depresyjne u osób w podeszłym wieku- przegląd literatury. Gerontologia Polska. 2015; 4: 165–169.
  31. Rado J, Janicak PG. Aripiprazole for late-life schizophrenia. Clin Interv Aging. 2010; 5: 253–258.
  32. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003; 64(9): 1048–1056.
  33. Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006; 189(2): 259–266.
  34. Madhusoodanan S, Brenner R, Gupta S, et al. Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS Spectr. 2004; 9(11): 862–867.
  35. Bharadwaj B, Kattimani S, Mukherjee A. Aripiprazole for acute mania in an elderly person. Ind Psychiatry J. 2011; 20(2): 142–144.
  36. Wu WY, Chan HY, Tan HKL. Suppression of antipsychotic-induced tardive dyskinesia with aripiprazole in an elderly patient with bipolar I disorder. Acta Neuropsychiatr. 2014; 26(1): 61–64.
  37. Carton L, Cottencin O, Lapeyre-Mestre M, et al. Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends. Curr Pharm Des. 2015; 21(23): 3280–3297.
  38. Kirino E. Use of aripiprazole for delirium in the elderly: a short review. Psychogeriatrics. 2015; 15(1): 75–84.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl